Dizal (Jiangsu) Pharmaceutical Co., Ltd. Share Price
Equities
688192
CNE1000055W8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.32 CNY | -3.25% |
|
-1.84% | -7.43% |
| Capitalization | 24.8B 3.64B 3.14B 2.87B 2.74B 5.02B 350B 5.1B 34.4B 13.31B 166B 13.68B 13.38B 578B | P/E ratio 2026 * |
-99.4x | P/E ratio 2027 * | 73.7x |
|---|---|---|---|---|---|
| Enterprise value | 24.8B 3.64B 3.14B 2.87B 2.74B 5.02B 350B 5.1B 34.4B 13.31B 166B 13.68B 13.38B 578B | EV / Sales 2026 * |
18.4x | EV / Sales 2027 * | 11.7x |
| Free-Float |
35.99% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.25% | ||
| 1 week | -1.84% | ||
| Current month | -5.96% | ||
| 1 month | -12.66% | ||
| 3 months | -0.98% | ||
| 6 months | -18.28% | ||
| Current year | -7.43% |
| 1 week | 52.16 |  | 58.58 |
| 1 month | 52.16 | | 60.19 |
| Current year | 46.66 | | 71.26 |
| 1 year | 46.66 | | 86.18 |
| 3 years | 24.82 | | 86.18 |
| 5 years | 19.02 | | 86.18 |
| 10 years | 19.02 | | 86.18 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Lin Zhang
CEO | Chief Executive Officer | 62 | 25/10/2017 |
Hong Bin Lu
DFI | Director of Finance/CFO | 48 | 07/09/2020 |
Zhi Wei Zhang
COO | Chief Operating Officer | 43 | 31/01/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Simon Lü
BRD | Director/Board Member | 58 | 30/09/2017 |
| Director/Board Member | 53 | 30/09/2017 | |
Bin Jiang
BRD | Director/Board Member | 62 | 07/09/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.25% | -1.84% | -5.36% | +15.14% | 3.64B | |
| -0.14% | +3.34% | +37.43% | +87.05% | 50.1B | |
| +0.12% | -3.44% | +68.07% | +49.81% | 45.82B | |
| -5.60% | +7.69% | +60.22% | +493.80% | 23.66B | |
| -2.65% | -4.86% | -3.47% | -15.20% | 22.65B | |
| +3.19% | +3.12% | +43.01% | -27.88% | 17.8B | |
| -1.66% | +2.59% | +27.48% | -40.75% | 16.08B | |
| -2.91% | -10.30% | +43.95% | +184.83% | 14.14B | |
| -7.00% | -6.69% | -29.33% | +995.45% | 13.09B | |
| +0.41% | -2.37% | +35.93% | - | 13B | |
| Average | -1.95% | -2.65% | +27.79% | +193.58% | 22B | |
| Weighted average by Cap. | -1.38% | -1.39% | +37.43% | +157.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.34B 198M 170M 155M 148M 272M 18.95B 276M 1.86B 722M 9B 741M 726M 31.35B | 2.11B 310M 267M 244M 233M 427M 29.78B 434M 2.93B 1.13B 14.14B 1.16B 1.14B 49.26B |
| Net income | -249M -36.59M -31.48M -28.78M -27.46M -50.35M -3.51B -51.18M -345M -134M -1.67B -137M -134M -5.81B | 336M 49.33M 42.45M 38.81M 37.03M 67.89M 4.73B 69.01M 466M 180M 2.25B 185M 181M 7.83B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/26 | 53.32 ¥ | -3.25% | 4,042,761 |
| 14/05/26 | 55.11 ¥ | -2.60% | 3,744,971 |
| 13/05/26 | 56.58 ¥ | -1.08% | 2,840,566 |
| 12/05/26 | 57.20 ¥ | +0.32% | 5,136,447 |
| 11/05/26 | 57.02 ¥ | +4.97% | 6,144,865 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688192 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition